JP2023541375A5 - - Google Patents
Info
- Publication number
- JP2023541375A5 JP2023541375A5 JP2023513294A JP2023513294A JP2023541375A5 JP 2023541375 A5 JP2023541375 A5 JP 2023541375A5 JP 2023513294 A JP2023513294 A JP 2023513294A JP 2023513294 A JP2023513294 A JP 2023513294A JP 2023541375 A5 JP2023541375 A5 JP 2023541375A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- disease
- less
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071297P | 2020-08-27 | 2020-08-27 | |
| US63/071,297 | 2020-08-27 | ||
| PCT/US2021/047779 WO2022047052A1 (en) | 2020-08-27 | 2021-08-26 | α1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541375A JP2023541375A (ja) | 2023-10-02 |
| JP2023541375A5 true JP2023541375A5 (cg-RX-API-DMAC7.html) | 2024-09-02 |
Family
ID=80355724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513294A Pending JP2023541375A (ja) | 2020-08-27 | 2021-08-26 | α１Ａ－アドレナリン受容体アゴニスト及び使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230312524A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4204404A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023541375A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230058066A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115884964A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021334327A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3187076A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002276A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022047052A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11622949B1 (en) | 2022-08-04 | 2023-04-11 | Gad M. Gilad | Agmatine compositions for treatment of osteoarthritis |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1302902B (cg-RX-API-DMAC7.html) * | ||||
| US2161938A (en) * | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2919274A (en) * | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
| US3423422A (en) * | 1967-04-04 | 1969-01-21 | Dow Chemical Co | 2-(aryl)-2-imidazolines |
| JPS51106739A (en) * | 1975-03-12 | 1976-09-21 | Takeda Chemical Industries Ltd | Satsuchu satsudanizai |
| US4665095A (en) * | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| WO1997046556A1 (en) * | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| SG72827A1 (en) * | 1997-06-23 | 2000-05-23 | Hoffmann La Roche | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives |
| CA2246027A1 (en) * | 1998-08-27 | 2000-02-27 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| AU2003227623B2 (en) * | 2002-04-23 | 2010-05-20 | F. Hoffmann-La Roche Ag | Imidazolinylmethyl aralkylsulfonamides |
| CA2637312A1 (en) * | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| EP2238116B1 (en) * | 2008-02-04 | 2011-09-21 | F. Hoffmann-La Roche AG | Novel imidazolinylmethyl aryl sulfonamides |
| BRPI0907495A2 (pt) * | 2008-02-04 | 2019-02-26 | F. Hoffmann-La Roche Ag | sulfonamidas de imidazolinilmetil arila |
| EP2238113A1 (en) * | 2008-02-04 | 2010-10-13 | F. Hoffmann-La Roche AG | N-[3-bromo-2-chloro-4-(4, 5-dihydro-1h-imidazol-2-ylmethyl)-phenyl] -methanesulfoamide as alpha-1 a adrenergic partial agonist for the treatment of incontinence |
| WO2009100120A2 (en) * | 2008-02-04 | 2009-08-13 | Neurogen Corporation | Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines |
| JP4168086B1 (ja) * | 2008-04-16 | 2008-10-22 | 国立大学法人福井大学 | イミダゾリン誘導体 |
| JP2013199432A (ja) * | 2011-02-21 | 2013-10-03 | Univ Of Fukui | イミダゾリン誘導体 |
| WO2016105448A1 (en) * | 2014-12-22 | 2016-06-30 | Darryl Rideout | Imidazoline receptor type 1 ligands for use as therapeutics |
| JP2019506459A (ja) * | 2016-02-26 | 2019-03-07 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | アルファ−１−アドレナリン受容体アゴニスト療法 |
| US20180230105A1 (en) * | 2017-01-13 | 2018-08-16 | Regents Of The University Of Minnesota | Therapeutic compounds |
| WO2021081292A1 (en) * | 2019-10-25 | 2021-04-29 | Curasen Therapeutics, Inc. | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS |
-
2021
- 2021-08-26 EP EP21862751.1A patent/EP4204404A4/en active Pending
- 2021-08-26 MX MX2023002276A patent/MX2023002276A/es unknown
- 2021-08-26 AU AU2021334327A patent/AU2021334327A1/en active Pending
- 2021-08-26 WO PCT/US2021/047779 patent/WO2022047052A1/en not_active Ceased
- 2021-08-26 CA CA3187076A patent/CA3187076A1/en active Pending
- 2021-08-26 KR KR1020237007503A patent/KR20230058066A/ko active Pending
- 2021-08-26 US US18/022,949 patent/US20230312524A1/en active Pending
- 2021-08-26 JP JP2023513294A patent/JP2023541375A/ja active Pending
- 2021-08-26 CN CN202180051042.6A patent/CN115884964A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527769A5 (cg-RX-API-DMAC7.html) | ||
| DE60020726T2 (de) | Biaryletherderivate, die als inhibitoren der monoamin-wiederaufnahme nützlich sind | |
| BRPI0308696B8 (pt) | composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos | |
| BRPI0612803A2 (pt) | processo para preparar um composto | |
| AU2015220560A1 (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | |
| FR2842804A1 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| CA2688493A1 (en) | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | |
| EP3743413A1 (en) | Estrogen receptor-modulating compounds | |
| JP2023541375A5 (cg-RX-API-DMAC7.html) | ||
| JP2007500187A (ja) | キノリン誘導体および治療におけるその使用 | |
| JP2011529069A5 (cg-RX-API-DMAC7.html) | ||
| JP2010509334A5 (cg-RX-API-DMAC7.html) | ||
| JP2002526527A (ja) | タキキニン受容体拮抗剤としてのナフタレンカルボキシアミド | |
| WO2008157658A1 (en) | Deuterium-enriched montelukast | |
| TWI360540B (en) | Tetrahydroisoquinolylsulphonamide derivatives, the | |
| JP2025512777A5 (cg-RX-API-DMAC7.html) | ||
| JP2023552292A5 (cg-RX-API-DMAC7.html) | ||
| US5561135A (en) | N,N,N',N'-tetrasubstituted-1,2-ethanediamine derivative compounds | |
| JP2024536815A5 (cg-RX-API-DMAC7.html) | ||
| EP1960387B1 (fr) | Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu antagonistes du recepteur de l histamine h3 | |
| WO2020006152A1 (en) | N-substituted indoles and use as allosteric modulators of cannabinoid receptors | |
| JP2009501204A (ja) | アリピプラゾール塩 | |
| Borgman et al. | . alpha.-Methyldopamine derivatives. Synthesis and pharmacology | |
| JP2022525293A5 (cg-RX-API-DMAC7.html) | ||
| JP2023502794A5 (cg-RX-API-DMAC7.html) |